TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27669162
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavior therapy (CBT)
Study: 27669162
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive therapy (CT)
Study: 18266402
Drug: Once-daily inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily inhaled SFC 50 microg/100 microg
Study: 18266402
Drug: Twice-daily inhaled
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily inhaled FP 100 microg
Study: 16983913
Drug: Zhiling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhiling Capsule (ZC) - whole recipe, administered orally for 2 weeks
Study: 16983913
Drug: Disassembled recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disassembled recipe 1 (Western medicines) of ZC, administered orally for 2 weeks
Study: 16983913
Drug: Disassembled recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disassembled recipe 2 (Chinese medicines) of ZC, administered orally for 2 weeks
Study: 16983913
Drug: Pingxiao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingxiao Capsule (Control), administered orally for 2 weeks
Study: 14534336
Drug: Gentamicin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (0.3 percent, or 3 mg per milliliter) administered topically, three times daily for 14 days
Study: 14534336
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered topically, three times daily for 14 days
Study: 11264156
Drug: GM-CSF priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM-CSF priming (250 microg/m(2) twice daily for 5 days before treatment)
Study: 9247942
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg midazolam
Study: 9247942
Drug: 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg midazolam
Study: 8005970
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and cyclophosphamide every other month (Gr-I)
Study: 8005970
Drug: Steroid alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid alone (Gr-II)
Study: 3551327
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (preoperative Co‐60 teletherapy + radical surgery)
Study: 29093280
Drug: Weekly DPP‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly DPP‐4 inhibitor, trelagliptin
Study: 29093280
Drug: Daily DPP‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily DPP‐4 inhibitors
Study: 23817470
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g DHA/day from a microalgae source with 2.4 g/day carrier oil for 16 weeks
Study: 23817470
Drug: 4.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g/day olive oil for 16 weeks (control)
Study: 18323500
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (C+A)
Study: 16581062
Drug: Cyclooxygenase‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclooxygenase‐2 inhibitor parecoxib (n=20)
Study: 12974197
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks
Study: 9383258
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg/day
Study: 12974197
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks (after initial treatment with antihistamines)
Study: 26275718
Drug: Person-Centred Counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-Centred Counselling (8 weekly sessions lasting up to 1 hour)
Study: 26275718
Drug: Low-Intensity Cognitive
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Cognitive Behavioural Therapy (up to 8 weeks of self-help resources with guided telephone support lasting 20-30 minutes each)
Study: 8526167
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (0.14 mg in each nostril twice a day)
Study: 8526167
Drug: Ebastine tablets
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine tablets (10 mg as a single night dose)
Study: 1780092
Drug: Nimesulide (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (one suppository twice a day for 7 days)
Study: 1780092
Drug: Flurbiprofen (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (one suppository twice a day for 7 days)
Study: 28736139
Drug: Stop TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop TDF therapy
Study: 28736139
Drug: Continue TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue TDF therapy
Study: 26953856
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction program (8-week initial treatment plus a 10-month maintenance phase)
Study: 21845596
Drug: Continuation haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation haloperidol (0.5‐5 mg daily)
Study: 21845596
Drug: Haloperidol (0.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5‐5 mg daily)
Study: 7596886
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (10 mg/kg)
Study: 28783060
Drug: Nacadia® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nacadia® therapy garden design
Study: 25998500
Drug: Febuxostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (10 mg daily)
Study: 23003917
Drug: Initial periodontal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial periodontal treatment (test group, n = 20)
Study: 23003917
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal therapy (control group, n = 20)
Study: 18716365
Drug: Valsartan monotherapy
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan monotherapy (VM)
Study: 18716365
Drug: Amlodipine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine monotherapy (AM)
Study: 18716365
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + ACE inhibitor (VA)
Study: 18716365
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + ACE inhibitor (AA)
Study: 10319359
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (1000 IU daily)
Study: 1890479
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (IM)
Study: 28259476
Drug: First-line AR-targeted
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line AR-targeted therapy
Study: 25538174
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) followed by chemotherapy
Study: 19380866
Drug: Upfront chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront chemotherapy
Study: 19366755
Drug: Fluoroscopic guidance
Normalized name: Fluoroacetic acid F-18
DrugBank: Fluoroacetic acid F-18 (DB15202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic guidance for corticosteroid injections (n=32)
Study: 19366755
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections using landmarks (n=33)
Study: 16937961
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (SUPP; n = 17)
Study: 15252161
Drug: 4 h
Normalized name: Type 4 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h infusion of 120 g of mixed AAs
Study: 15252161
Drug: 4 h
Normalized name: Type 4 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h infusion of 50 g of L‐lysine
Study: 15252161
Drug: 10 h
Normalized name: POLYGLYCERYL-10 HEXAOLEATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 h infusion of 240 g of mixed AAs
Study: 15252161
Drug: 4 h
Normalized name: Type 4 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h infusion of 50 g of L‐lysine + L‐arginine (Lys‐Arg)
Study: 22875883
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion (control)
Study: 9036797
Drug: Intravenous cidofovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 weeks and then once every other week
Study: 9036797
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (no cidofovir until progression documented)
Study: 9058613
Drug: Intravenous cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cidofovir
Study: 9036797
Drug: Intravenous cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cidofovir with probenecid and saline hydration
Study: 7639363
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg intravenously
Study: 7639363
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg orally
Study: 29129715
Drug: Adapted Diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Diabetes Prevention Program Group Lifestyle Balance (DPP GLB) intervention, details on dosage and duration not specified.
Study: 29129715
Drug: Responsive adaptations
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Responsive adaptations during intervention delivery, details on dosage and duration not specified.
Study: 27145396
Drug: Online Lee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Lee Silverman Voice Treatment (LSVT LOUD)
Study: 27145396
Drug: Face‐to‐face Lee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face‐to‐face Lee Silverman Voice Treatment (LSVT LOUD)
Study: 27145396
Drug: Online treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online treatment (nonmetropolitan cohort)
Study: 27145396
Drug: Online treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online treatment (metropolitan cohort)
Study: 18374304
Drug: Face-to-face cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive-behavioral therapy (FTF-CBT)
Study: 18374304
Drug: Telemedicine cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine cognitive-behavioral therapy (TV-CBT)
Study: 11198206
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin IgG, 0.4 g/kg body weight/day for 5 consecutive days, followed by single booster doses of 0.4 g/kg/day, once a month for 9 months
Study: 11198206
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin IgG
Study: 8833099
Drug: 1 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg/day alcohol
Study: 8833099
Drug: 2 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg/day alcohol
Study: 8833099
Drug: 0 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg/day alcohol (control)
Study: 1428567
Drug: 0.5% maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% maleate timolol, twice a day for 7 days
Study: 6776576
Drug: (‐)‐deprenyl (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: (‐)‐deprenyl (5‐10 mg/day for 3 days)
Study: 30308286
Drug: Daily breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breath alcohol monitoring with reinforcement for alcohol-negative breath samples
Study: 30308286
Drug: Daily breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breath alcohol monitoring without reinforcement
Study: 30308286
Drug: Transdermal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal alcohol monitoring
Study: 30308286
Drug: Transdermal monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal monitoring
Study: 25796293
Drug: Oxycodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone with analgesia information sheet
Study: 23389323
Drug: sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sertraline hydrochloride (50 mg/d) + active tDCS (2‐mA anodal left/cathodal right prefrontal tDCS, twelve 30‐minute sessions)
Study: 17069818
Drug: Irbesartan (IRB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (IRB; 300 mg/d) for 12 weeks
Study: 17069818
Drug: Losartan (10(‐5)
Normalized name: losartan 12.5 MG
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (10(‐5) mol/L)
Study: 17069818
Drug: LY311727 (10(‐5)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY311727 (10(‐5) mol/L)
Study: 10194425
Drug: FAI +
Normalized name: Fludrocortisone acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAI + G-CSF
Study: 10194425
Drug: FAI +
Normalized name: Fludrocortisone acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAI + ATRA + G-CSF
Study: 10194425
Drug: FAI +
Normalized name: Fludrocortisone acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAI + G-CSF + ATRA
Study: 6106781
Drug: Isophosphamide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isophosphamide with mesnum (4 to 8 g/m2)
Study: 25782657
Drug: Probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic milk containing Lactobacillus rhamnosus GG, L acidophilus La-5, and Bifidobacterium animalis subsp. lactis Bb-12, administered from 36 weeks of gestation to 3 months postnatally.
Study: 23787030
Drug: 8-weeks of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-weeks of combination nicotine replacement therapy (NRT) in conjunction with brief counseling (SBIRT framework) (n=23)
Study: 16855076
Drug: Lidocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (4 mg/kg; maximal dose 300 mg)
Study: 16855076
Drug: Oxycodone/acetaminophen (10/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen (10/650 mg)
Study: 16855076
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (diphenhydramine, 50 mg)
Study: 10818327
Drug: remifentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil + propofol (0.1 mg/kg/min)
Study: 6623770
Drug: 5,000 units
Normalized name: Lapase, 1200 units-15,000 units-15,000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 units of subcutaneous heparin three hours preoperatively and every twelve hours thereafter for forty-eight hours
Study: 6623770
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injections in a similar manner
Study: 17461902
Drug: docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (T) 75 mg/m(2), epirubicin (E) 75 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Study: 17461902
Drug: docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (T) 100 mg/m(2), epirubicin (E) 100 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Study: 15033849
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use in RSV infected children
Study: 11243558
Drug: B&L pinch
Approvals — FDA: no, EMA: no, PMDA: no
Description: B&L pinch gauge
Study: 3593897
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g) before ketoprofen (50 mg)
Study: 3593897
Drug: Ketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (50 mg) alone
Study: 3593897
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g) before indomethacin (50 mg)
Study: 3593897
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg) alone
Study: 3593897
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g) before naproxen (500 mg)
Study: 3593897
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg) alone
Study: 28476259
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg orally for 4 days)
Study: 24635755
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) 0.5 mg + intravitreal triamcinolone acetonide (IVTA) 1 mg
Study: 16548351
Drug: Sanqi tablet
Normalized name: Sanqi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanqi tablet (SQT)
Study: 12517464
Drug: Antidepressant (fluoxetine)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (fluoxetine)
Study: 29659187
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of anastrozole 1.0-mg tablet
Study: 29659187
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of anastrozole (Arimidex 1.0-mg tablet)
Study: 25458048
Drug: Parecoxib 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 0.5 mg/kg
Study: 25458048
Drug: Morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 50 μg/kg
Study: 22551976
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA) treatment
Study: 15699689
Drug: Fructo-oligosaccharide formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharide formula (1.5 g/L)
Study: 15699689
Drug: Fructo-oligosaccharide formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharide formula (3.0 g/L)
Study: 10446816
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg every 6 hrs for a total of four doses
Study: 10446816
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg as a single dose
Study: 7844602
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) genetically modified with a retroviral vector containing the NeoR gene.
Study: 2085872
Drug: Nitrate therapy
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate therapy (2 x 20 mg IS‐5‐MN and 1 x 120 mg ISDN sustained release)
Study: 454092
Drug: MAO inhibitors
Normalized name: MAO inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAO inhibitors
Study: 22525398
Drug: Ribosome-component immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribosome-component immune modulator (RCIM)
Study: 16096858
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 250 mg twice a week for 12 weeks
Study: 9951979
Drug: SB MMR
Normalized name: MMR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB MMR vaccine (Priorix; SmithKline Beecham Biologicals)
Study: 9951979
Drug: Merck MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck MMR vaccine (M‐M‐R II; Merck & Co. Inc)
Study: 35211
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg three times daily
Study: 29317191
Drug: Ramucirumab 10
Normalized name: ramucirumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 10 mg/kg every 2 weeks with erlotinib 150 mg/d
Study: 25679172
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose calculation during optimization
Study: 10871094
Drug: Serial doses
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial doses printed on polyester squares
Study: 9339881
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75 mg once daily
Study: 9339881
Drug: Venlafaxine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine IR 37.5 mg twice daily
Study: 3518765
Drug: Atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.6 mg kg‐1 (Group I, 20 patients)
Study: 3518765
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg kg‐1 (Group II, 10 patients)
Study: 29970072
Drug: Arctostaphylos uva‐ursi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arctostaphylos uva‐ursi (UU, bearberry extract arbutin) 105 mg, 3 times a day for 5 days
Study: 29970072
Drug: Fosfomycin 3
Normalized name: fosfomycin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin 3 g once
Study: 25917376
Drug: Monthly structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly structured pharmaceutical care visits delivered by pharmacists for 6 months
Study: 20107144
Drug: Anthelmintic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic treatment at 0 and 3 months
Study: 20107144
Drug: Iron-fortified biscuits
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified biscuits providing an additional 20 mg iron/d as electrolytic iron 4 times/week
Study: 15990345
Drug: Tidal breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal breathing method with capsaicin 0.4 micromol/L
Study: 15990345
Drug: Dosimeter method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosimeter method with capsaicin 0.4 micromol/L